Furthermore, miR-221 inhibits latent TGF-β1 activation through targeting thrombospondin-1 (THBS1), a key activator of TGF-β1, thereby attenuating kidney failure-induced cardiac fibrosis. Here, TGFB1 is linked to kidney failure.